2017
DOI: 10.18632/oncotarget.17299
|View full text |Cite
|
Sign up to set email alerts
|

PRAS40 signaling in tumor

Abstract: The proline-rich Akt substrate of 40 kDa (PRAS40) is a substrate of Akt and a component of the mammalian target of rapamycin complex 1 (mTORC1). Locating at the crossroad of the PI3K/Akt pathway and the mTOR pathway, PRAS40 is phosphorylated by growth factors or other stimuli, and regulates the activation of these signaling pathways in turn. PRAS40 plays an important role in metabolic disorders and multiple cancers, and the phosphorylation of PRAS40 is often associated with the tumor progression of melanoma, p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
43
0
2

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 51 publications
(47 citation statements)
references
References 71 publications
(145 reference statements)
2
43
0
2
Order By: Relevance
“…PRAS40 is a downstream target of AKT, a component of the mTOR complex 1 (mTORC1) that regulates mTOR activity, and when phosphorylated dissociates from mTORC1 so that it can function . PRAS40 is increasingly used as a biomarker of AKT activation in tumors . The mTOR inhibitor sirolimus (rapamycin) has been used to treat KLA patients with a partial response in KLA patients .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…PRAS40 is a downstream target of AKT, a component of the mTOR complex 1 (mTORC1) that regulates mTOR activity, and when phosphorylated dissociates from mTORC1 so that it can function . PRAS40 is increasingly used as a biomarker of AKT activation in tumors . The mTOR inhibitor sirolimus (rapamycin) has been used to treat KLA patients with a partial response in KLA patients .…”
Section: Discussionmentioning
confidence: 99%
“…[15][16][17][18][19] In the Glaser study, 6 PRAS40 is increasingly used as a biomarker of AKT activation in tumors. 21 The mTOR inhibitor sirolimus (rapamycin) has been used to treat KLA patients with a partial response in KLA patients. 2 24 and has now been granted "Fast Track" designation by the Food and Drug Administration for the treatment of PROS as well as Rare Pediatric Disease designation for the treatment of Proteus syndrome.…”
Section: Discussionmentioning
confidence: 99%
“…This observation suggests that the PI3K/Akt and mTOR pathways might be involved in the anticancer activity of 3. The cytoplasmic form of PRAS40 is indeed known to play a role in the regulation of these two signaling pathways by directly regulating the mTORC1 kinase activity [33,34]. To determine whether p53 phosphorylation on serine 15 was a result of DNA damage induced by 3, MCF7-Sh-WISP2 cells were immuno-labelled with the γ-H2AX antibody following exposure to 3 ( Figure S4).…”
Section: Cytotoxic Activity Of 1-4 Toward Mcf7 Mcf7-sh-wisp2 and 3t3mentioning
confidence: 99%
“…6e, f). We then detected the level of p-p70S6K, a major downstream target of mTOC1, because the dephosphorylation of PRAS40 and AMPK activation could both indirectly inhibit mTOC1 activity to negatively regulate protein synthesis [17][18][19] . The results revealed that the phosphorylation of p70S6K was strongly repressed in response to the increased p-AMPK and decreased p-PRAS40 caused by PTP1B inhibition (Fig.…”
Section: Ptp1b Regulates Pancreatic Cancer Cell Growth Via the Pkm2/amentioning
confidence: 99%